ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 155 filers reported holding ASCENDIS PHARMA A/S in Q3 2020. The put-call ratio across all filers is 0.38 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $11,828,000 | +54.9% | 76,643 | +48.4% | 0.09% | +33.3% |
| Q2 2020 | $7,638,000 | +115.7% | 51,643 | +64.2% | 0.07% | +73.7% |
| Q1 2020 | $3,541,000 | -49.1% | 31,443 | -37.1% | 0.04% | -37.7% |
| Q4 2019 | $6,956,000 | +188.9% | 50,000 | +100.0% | 0.06% | +177.3% |
| Q3 2019 | $2,408,000 | -16.4% | 25,000 | 0.0% | 0.02% | -12.0% |
| Q2 2019 | $2,879,000 | -18.7% | 25,000 | -50.0% | 0.02% | -16.7% |
| Q3 2018 | $3,543,000 | +6.5% | 50,000 | 0.0% | 0.03% | +50.0% |
| Q2 2018 | $3,326,000 | +1.7% | 50,000 | 0.0% | 0.02% | -39.4% |
| Q1 2018 | $3,270,000 | +8.8% | 50,000 | -33.3% | 0.03% | +6.5% |
| Q4 2017 | $3,005,000 | – | 75,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |